Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.

April 01, 2019 By:
  • Johannessen TC
  • Hasan-Olive MM
  • Zhu H
  • Denisova O
  • Grudic A
  • Latif MA
  • Saed H
  • Varughese JK
  • Rosland GV
  • Yang N
  • Sundstrom T
  • Nordal A
  • Tronstad KJ
  • Wang J
  • Lund-Johansen M
  • Simonsen A
  • Janji B
  • Westermarck J
  • Bjerkvig R
  • Prestegarden L.

Glioblastoma multiforme (GBM) has a poor prognosis with an overall survival of 14-15 months after surgery, radiation and chemotherapy using temozolomide (TMZ). A major problem is that the tumors acquire resistance to therapy. In an effort to improve the therapeutic efficacy of TMZ, we performed a genome-wide RNA interference (RNAi) synthetic lethality screen to establish a functional gene signature for TMZ sensitivity in human GBM cells. We then queried the Connectivity Map database to search for drugs that would induce corresponding changes in gene expression. By this approach we identified several potential pharmacological sensitizers to TMZ, where the most potent drug was the established antipsychotic agent Thioridazine, which significantly improved TMZ sensitivity while not demonstrating any significant toxicity alone. Mechanistically, we show that the specific chemosensitizing effect of Thioridazine is mediated by impairing autophagy, thereby preventing adaptive metabolic alterations associated with TMZ resistance. Moreover, we demonstrate that Thioridazine inhibits late-stage autophagy by impairing fusion between autophagosomes and lysosomes. Finally, Thioridazine in combination with TMZ significantly inhibits brain tumor growth in vivo, demonstrating the potential clinical benefits of compounds targeting the autophagy-lysosome pathway. Our study emphasizes the feasibility of exploiting drug repurposing for the design of novel therapeutic strategies for GBM.

2019 Apr. Int J Cancer.144(7):1735-1745. Epub 2018 Dec 11.
Other information